AdAlta has raised $2.5 million from sophisticated investors to accelerate development of its lead CAR T therapy, BZDS1901, and to progress manufacturing and regulatory milestones in Australia and the United States. …
AdAlta secures funds to advance CAR-T therapy after positive clinical responses
May 4, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 - - Latest News -
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News